Tipifarnib in Treating Young Patients With Refractory Leukemia
This study has been completed.
Children's Oncology Group
Information provided by:
National Institutes of Health Clinical Center (CC)
First received: August 10, 2001
Last updated: March 14, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||March 2005|
|Estimated Primary Completion Date:||No date given|
Widemann BC, Arceci RJ, Jayaprakash N, Fox E, Zannikos P, Goodspeed W, Goodwin A, Wright JJ, Blaney SM, Adamson PC, Balis FM. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Feb;56(2):226-33. doi: 10.1002/pbc.22775. Epub 2010 Sep 21.